R. Stephanie Huang, PhD

Bridging Pre-Clinical Drug Screening with Patient Molecular Profiles for Biomarker Discovery and Drug Repurposing


November 2, 2018 | 2:00 to 3:00 p.m. | 2-650 Moos Tower

Note special location for this seminar

Dr. Huang’s research focuses on translational pharmacogenomics with particular interest in anticancer agents. By systematically evaluating the human genomes and their relationships to drug response and toxicity, her goal is to develop clinically useful models that predict risks for adverse drug reactions and non-response prior to administration of chemotherapy. Her lab conducts research through cutting-edge computational and experimental methods. Utilizing cell lines (derived from healthy and disease individuals as well as commercially available cancer cell lines), and clinical samples, the Huang lab discovers and functionally characterizes genetic variations, gene and non-coding RNA (i.e., microRNA, lncRNA) expression for their role in chemotherapeutic sensitivity.